Instylla Inc
Bedford, US · Founded 2017 · Delaware corporation · 77 employees on LinkedIn · 4 known investors
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels. Its products are used by physicians treating hypervascular tumors in the peripheral vasculature.
Founders & leadership
Instylla Inc was founded in 2017 by Amarpreet Sawhney.
AS
Amarpreet SawhneyFounder
RL
Raymond LareauinChief Technology Officer
SC
Steven CagnettaExecutive
SB
Sean BoyleinChief Executive Officer
Board
HC
TD
TB
DZ
Darshana ZaveriBoard director
FK
Farhad KhosraviBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$128.8M disclosed across 5 rounds · 2017–2025
▶$34.8MraisedJul 2026 · 29 investors · BiotechnologyRule 506(b)
▶$34.8MraisedJul 2026 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amarpreet SawhneyExecutive Officer
- Henry ChenDirector
- Tasneem DohadwalaDirector
- Farhad KhosraviDirector
- Darshana ZaveriDirector
- Steven CagnettaExecutive Officer
- Sean ChengDirector
- Daniel DavisDirector
- Sean BoyleDirector
- Offering amount
- $35M
- Amount sold
- $34.8M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.3MraisedNov 2023 · 32 investors · BiotechnologyRule 506(b)
▶$30.3MraisedNov 2023 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ray LareauDirector
- Amarpreet SawhneyExecutive Officer, Director
- Darshana ZaveriDirector
- Tara ButlerDirector
- Tasneem DohadwalaDirector
- Farhad KhosraviDirector
- Offering amount
- $30.3M
- Amount sold
- $30.3M
- Minimum investment
- $10K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.3MraisedNov 2023 · 32 investors · BiotechnologyRule 506(b)
▶$30.3MraisedNov 2023 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tara ButlerDirector
- Farhad KhosraviDirector
- Ray LareauDirector
- Darshana ZaveriDirector
- Tasneem DohadwalaDirector
- Amarpreet SawhneyExecutive Officer, Director
- Offering amount
- $30.3M
- Amount sold
- $30.3M
- Minimum investment
- $10K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.4MraisedOct 2020 · 17 investors · BiotechnologyRule 506(b)
▶$25.4MraisedOct 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amarpreet SawhneyExecutive Officer, Director, Promoter
- Tara ButlerExecutive Officer, Director, Promoter
- Patrick CampbellExecutive Officer, Director, Promoter
- Farhad KhosraviExecutive Officer, Director, Promoter
- Offering amount
- $25.4M
- Amount sold
- $25.4M
- Minimum investment
- $50K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$8.1MraisedJun 2017 · 5 investors · BiotechnologyRule 506(b)
▶$8.1MraisedJun 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tara ButlerDirector
- Farhad KhosraviDirector
- Amarpreet SawhneyExecutive Officer, Director
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- Minimum investment
- $25K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Fortis Life Sciences8 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Boston Scientific7 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Companies competing with Instylla Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Instylla Inc do?
- Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels. Its products are used by physicians treating hypervascular tumors in the peripheral vasculature.
- Who founded Instylla Inc?
- Instylla Inc was founded by Amarpreet Sawhney in 2017.
- Who are Instylla Inc's investors?
- Instylla Inc's investors include Angel Physicians Fund, Ascension Ventures, Delos Capital, Excelestar Ventures.
- How much funding has Instylla Inc raised?
- Instylla Inc has disclosed $128.8M raised across 5 rounds.
- Where is Instylla Inc headquartered?
- Instylla Inc is headquartered in Bedford, US.